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Abstract
Metabolic syndrome (MS) is a constellation of metabolic derangements associated with vascular endothelial dysfunction
and oxidative stress and is widely regarded as an inflammatory condition, accompanied by an increased risk for
cardiovascular disease. The present study tried to investigate the implications of telomerase activity with inflammation and
impaired endothelial function in patients with metabolic syndrome. Telomerase activity in circulating peripheral blood
mononuclear cells (PBMC), TNF-a, IL-6 and ADMA were monitored in 39 patients with MS and 20 age and sex-matched
healthy volunteers. Telomerase activity in PBMC, TNF-a, IL-6 and ADMA were all significantly elevated in patients with MS
compared to healthy volunteers. PBMC telomerase was negatively correlated with HDL and positively correlated with
ADMA, while no association between TNF-a and IL-6 was observed. IL-6 was increasing with increasing systolic pressure
both in the patients with MS and in the healthy volunteers, while smoking and diabetes were positively correlated with IL-6
only in the patients’ group. In conclusion, in patients with MS characterised by a strong dyslipidemic profile and low
diabetes prevalence, significant telomerase activity was detected in circulating PBMC, along with elevated markers of
inflammation and endothelial dysfunction. These findings suggest a prolonged activity of inflammatory cells in the studied
state of this metabolic disorder that could represent a contributory pathway in the pathogenesis of atherosclerosis.
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Introduction
Metabolic syndrome (MS) is a constellation of metabolic
derangements commonly coexisting in the same patient that has
reached epidemic proportions [1]. A cluster of cardiovascular and
pro-thrombotic risk factors, such as insulin resistance, impaired
glucose tolerance, dyslipidemia, obesity and elevated blood
pressure characterize MS. MS is reported to be associated with
vascular endothelial dysfunction and oxidative internal milieu [2]
and is widely regarded as an inflammatory condition [3,4],
accompanied by an increased risk for cardiovascular disease [5].
MS represents a combination of synergistic vascular pathologies
that lead to an accelerated atherogenic state that compromises the
ability of the patient to satisfactorily respond to humoral, cellular,
and mechanical stresses.
Endothelial dysfunction with impaired nitric oxide (NO)
bioavailability has been implicated in insulin resistance and
hypertension. Asymmetric dimethyl arginine (ADMA) is linked
to the impairment of endothelial, NO-dependent, function by
inhibiting endogenous nitric oxide synthetase in a concentration-
dependent manner, and has been associated with cardiovascular
diseases [6,7,8].
Telomerase activity is crucial for preservation of telomeres’
function and structure [9]. Telomeres, the ends of eukaryotic
chromosomes, are structures strictly related to the phenomenon of
cellular senescence [10]. Cellular senescence occurs after an
extended period of cell divisions, but it can occur earlier in case the
cell is exposed to various types of stresses, oxidative stress being
one of them [9]. Telomerase activity may also be interrelated to
inflammation, especially in cell types like peripheral blood
mononuclear cells (PBMC) implicated in this process [11]. Soluble
CD163 (sCD163) represents a monocyte/macrophage-specific
scavenger receptor cleaved under the effect of inflammatory
stimuli and subsequently released systemically from monocyte/
macrophage cell membranes, suggesting that sCD163 is a marker
of monocyte/macrophage activation [12].
The present study tried to investigate the implications of
telomerase activity with inflammation and impaired endothelial
function in patients with metabolic syndrome.
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Participants
Patients were classified based on the presence or absence of MS
at baseline using the AHA/NHLBI definition [13]: triglycerides
$150 mg/dL; high-density lipoprotein cholesterol (HDL)
,40 mg/dL in males or ,50 mg/dL for females; blood pressure
(BP) $130/85 mm Hg or treatment with antihypertensive
medications; and fasting blood glucose $100 mg/dL or treatment
with oral hypoglycaemic drugs or insulin injection; waist
circumference $102 cm (men), $88 cm (women). Patients who
had 3 of 5 criteria were regarded as having MS. Thirty nine (39)
patients with MS treated on a regular basis at the ‘‘Amalia
Fleming’’ General Hospital in Athens, Greece, volunteered to
participate in the study. Twenty (20) age and sex-matched healthy
volunteers were also used as reference for normal population
values of TNF-a, IL-6, ADMA and telomerase activity that were
monitored.
Description of Procedures or Investigations undertaken
In the morning and after an at-least-30-min supine rest, non-
fasting venous blood samples were drawn from all patients and
healthy volunteers, centrifugated within 30 min and stored at
220uC. Serum samples were later analysed for ADMA using an
ADMA-ELISA kit (DLD) (sensitivity 0.05 mmol/l, upper limit of
the working range 5.0 mmol/l, mean intra-assay variation 6.05%).
TNF-a and IL-6 were measured using the IMMULITEH
1000TNF-a (sensitivity 1.7 pg/ml, upper limit of the working
range 1000 pg/ml, mean intra-assay variation 3.2%) and
IMMULITEH 1000IL-6 (sensitivity 2 pg/ml, upper limit of the
working range 1000 pg/ml, mean intra-assay variation 4.65%)
assays (Siemens). sCD163 was determined using an ELISA kit
from Trillium Diagnostics as previously described [12]. The
method for detection of telomerase activity and isolation of PBMC
is described elsewhere [14]. Briefly, telomerase activity in PBMC
was measured using a commercial telomerase PCR-ELISA (Roche
Diagnostics Corp., Indianapolis, IN, USA), based on the telomeric
repeat amplification protocol [15].
Ethics
Written informed consents were obtained from all participants.
The research ethics committee of the ‘‘Amalia Fleming’’ Hospital
approved the procedures. The Declaration of Helsinki (2000) and
the applicable national standards as they relate to the involvement
of human subjects in research were enforced. No external funding
was received for this study.
Statistical methods
All results are presented as mean values 6 SD. Statistical
analyses were performed with SPSS version 14 (SPSS Inc.,
Chicago, IL, USA). Significant differences between means for the
same parameters were investigated with repeated measures
ANOVA and paired t-test analyses. Independent t-tests were used
to compare mean values between groups. Pearson and Spearman
correlations and linear regression analysis was conducted to
investigate associations between various variables. Differences
between categorical variables were assessed by the chi-square test.
Multiple linear regression analyses after log transformation of the
dependent variable, since the distribution was skewed, were
performed to evaluate the relationship between PBMC telomerase
activity and factors associated with the development of cardiovas-
cular risk (hypertension, diabetes, smoking, hyperlipidemia, waist
circumference). Multiple linear regression analyses with backward
selection was applied to investigate the correlation between PBMC
telomerase activity and ADMA. A list of possible confounders
(hypertension, diabetes, smoking, hyperlipidemia, waist circum-
ference) was included in the initial variables set. A p-value #0.05
was considered statistically significant.
Results
Thirty-nine patients (mean age 5469.9 years) were included in
the study. Table 1 summarizes the demographic, clinical and
epidemiological characteristics of patients and healthy volunteers
and values for all biochemical parameters monitored. The MS
patients of this study are characterised by disturbed lipidemic
profile (92.1% elevated TG, 89,4% low HDL) and obesity (100%
abnormal waist circumference), while the prevalence of diabetes
was 38.5% and of hypertension 52.6%.
Telomerase activity in PBMC, TNF-a, IL-6, sCD163 and
ADMA were all significantly elevated in patients with MS
compared to healthy volunteers.
Upon analysis of all patients with MS for factors associated with
the development of cardiovascular risk by multiple linear
regression, significant negative correlations were only found
between PBMC telomerase activity and HDL (r=20.653,
p=0.021 and waist circumference (r=20.621, p=0.031). PBMC
telomerase activity was also positively correlated with ADMA
(r=0.604, p=0.038) and sCD163 (r=0.556, p=0.044), while no
association between TNF-a and IL-6 and PBMC telomerase
activity was observed. sCD163 were nearly significantly correlated
with ADMA (r=0.445, p=0.058) and TNF-a (r=0.301,
p=0.064).
TNF-a was found statistically increased in females compared to
males only in the patients group. Telomerase activity, IL-6 and
ADMA levels did not differ with sex. It should be noted, though,
that the average age of women enrolled in the patients’ group
(51.765.45 years) was statistically higher (p=0.022) compared to
the healthy volunteers (35.665.18 years) and did not differ from
the average age of male patients (54.5610.9 years). Women above
the average age of menopause (51 years) [16] are losing with
increasing age the anti-inflammatory and vasoprotective effects of
estrogens [17]. Waist circumference was again negatively corre-
lated to TNF-a (r=0.613, p=0.019).
IL-6 was increasing with increasing systolic pressure both in the
patients with MS and in the healthy volunteers (r=0.354,
p=0.047), while smoking and diabetes were positively correlated
with IL-6 only in the patients’ group.
Discussion
To the authors’ knowledge, this is the first study to report on
elevated telomerase activity in PBMC of patients with MS.
Previous studies on haemodialysis and diabetic patients [18,19]
and patients with rheumatoid arthritis [20] have found lower
PBMC telomerase activity suggesting that in a cell type like
PBMC, which is directly implicated in the inflammatory process, it
is generally expected a pre-mature senescence for a higher
inflammatory activity [21]. On the other hand, PBMC telomerase
levels measured in our study are comparable with those recently
reported for overweight African Americans [22]. Furthermore,
MS may be an important contributory factor for coronary artery
disease through increased oxidative stress and induces subclinical
atherosclerosis [2]. In that sense our results coincide with those
reported on elevated polymorphonuclear neutrophils (PMN)
telomerase in patients with unstable angina [23] and suggest a
systemic activation of blood cells of the immune system. Garlichs
et al. [24] have recently observed a marked delay of circulating
PMN apoptosis in patients with acute coronary syndromes.
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consistent and persisting inflammation state, as neutrophil
apoptosis has been identified to be one of the key mechanism to
switch off inflammation [23]. In the same line of evidence, Gizard
et al. found activated telomerase in macrophages [25].
Recently, a significant role in the regulation of the immune
response accompanying atherosclerosis has been ascribed to
interactions between activated T cells, promoting the expression
of systemic inflammatory response factors participating in
atherogenesis, such as TNF–a and IL-6 [26,27]. Both TNF-a
and IL-6 were found elevated in the MS patients of the present
study, which is in accordance with the vascular biology described
for MS [5]. TNF-a doesn’t seem to correlate either with insulin
resistance or with endothelial dysfunction in men with MS [28]. In
the present study no association between TNF-a and IL-6 and
PBMC telomerase activity was observed probably due to different
and multi-factorial underlying activation mechanisms possibly
involving endothelial damage and oxidative stress. Furthermore,
systemic cytokines levels may underestimate local inflammation.
The elevation of sCD163 reported in our MS patients provides
new information that the increased telomerase activity in PMBCs
coexists with monocyte/macrophage activation. A recent study
has revealed that monocyte/macrophage activation, as reflected
by sCD163 levels, is strongly associated with HOMA-IR in
normal-weight and obese subjects and thus may be an important
determinant of insulin resistance in obesity [12].
Numerous metabolic abnormalities found in the metabolic
syndrome cause an endothelial cell dysfunction by affecting NO
synthesis or degradation [29]. There is evidence that NO possesses
anti-inflammatory and anti-atherosclerotic properties [30].
ADMA increases in MS [6], although ethnic-specific or environ-
mental differences may influence its levels [31]. We currently
report strong positive correlation of PBMC telomerase activity
with elevated serum ADMA in the MS patients of the present
study. An ADMA-induced cycle of PMN activation has recently
been reported [32]. Furthermore, endothelial impairment and
activation of telomerase are both enhanced through the NF-kB
transcription factor action: endothelial adhesion molecules are
expressed in mononuclears in atherosclerotic lessions, with the
current mediation of TNF-a pro-inflammatory effect [33] and the
expression of the catalytic subunit telomerase reverse transcriptase
(TERT) is induced in macrophage [25]. The nearly significant
correlation of elevated sCD163 with ADMA and TNF-a in our
MS patients could support the view that endothelial dysfunction
through mediated TNF-a mechanisms lies behind the reported
prolonged PBMC life cycle. In line with this conclusion, Satoh et
Table 1. Demographic and clinical characteristics and biochemical parameters monitored in the patients of the study group and
the healthy individuals that provided reference values for all biochemical parameters (healthy controls).
Demographic and Clinical Characteristics Healthy controls Patients with metabolic syndrome P
a
Gender Male 15 29 0.911
Female 5 9
Age (years) 56610 (31–60) 5469.9 (33–69) 0.723
Waist circumference (cm) 114617.6 (78–135) 129615.8 (105–160) 0.002
Hypertension (mmHg) YES 2 (90–145) 20 (92–145) 0.001
NO 18 (68–125) 18 (70–122)
Diabetes Mellitus (DB) YES 0 16 0.001
NO 20 22
Triglycerides (TG) (mg/dl)
b 127652.4 (46.1–230) 259672.0 (138–422) 0.000
LDL (mg/dl) 130624.3 (80.2–177) 147635.0 (76.2–250) 0.220
HDL (mg/dl) 47.168.61 (24.1–59.7) 43.469.91 (26.2–64.1) 0.037
Smoking 9 16 0.832
Family history of Coronary Disease 5 10 0.933
Chronic kidney failure 0 1 -
General surgical operations 1 10 -
ACEI
3 administration 0 10 -
Statins administration 0 8 -
Vascular disease 0 0 -
TNF-a (pg/ml) 9.1863.93 35.6624.5 0.003
IL-6 (pg/ml) 8.8963.34 34.9624.8 0.006
ADMA (mmol/ml) 1.1560.43 2.0760.67 0.014
Telomerase activity (OD)
4 0.6760.28 1.6760.60 0.002
sCD163 (ng/ml) 5346164 8766301 0.032
Values are means6SD.
aComparison between Patients with metabolic syndrome and Healthy controls.
bNormal values or range of values for general population: TG 0–160 mg/dl, LDL optimal .100 mg/dl near optimal 100–1129 mg/dl above optimal 130–159 mg/dl borderline
high 160–189 mg/dl high .190 mg/dl, HDL .55 mg/dl (male), .65 mg/dl (female).
LDL: low–density lipoprotein cholesterol; HDL: high–density lipoprotein cholesterol; TNF-a: Tumor necrosis factor a; ACEI: angiotensin converting enzyme inhibitor; OD: Optical
Density.
doi:10.1371/journal.pone.0035739.t001
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with oxidative DNA damage, in endothelial progenitor cells (EPC)
of patients suffering from coronary artery disease (CAD), this being
even more intense in CAD patients with MS, inducing endothelial
cell senescence and dysfunction [34]. Damage to the endothelium
may thus be the key factor in the promotion of the atherogenic and
inflammatory process in MS.
The high anti-oxidant and anti-inflammatory activities of HDL,
which are associated with protection from cardiovascular disease
[35] have become evident in the present study through the
negative correlation found with PBMC telomerase activity. The
association of telomerase activity with anthropometric measures,
such as waist circumference and BMI, remains unclear in the
literature [36,37] and the negative correlations of waist circum-
ference with PBMC telomerase activity and TNF-a observed in
our MS patients needs to be further elucidated. Cardiovascular
risk factors, such as smoking and hypertension don’t correlate with
PBMC telomerase activity, in agreement with previously published
data [23], but strongly affect IL-6 in the present study.
In conclusion, in patients with MS with a strong dyslipidemic
profile and low diabetes prevalence, significant telomerase activity
was detected in the circulating PBMC, along with elevated
markers of inflammation and endothelial dysfunction. These
findings suggest a prolonged activity of inflammatory cells in the
studied state of this metabolic disorder that could represent a
contributory pathway in the pathogenesis of atherosclerosis.
Further studies are warranted in order to establish the precise
prognostic value of telomerase reactivation in MS.
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